Actelion’s Opsumit drug missed a primary endpoint in a late-stage study of patients with pulmonary arterial hypertension due to Eisenmenger Syndrome, a doctor involved in the trial said in a statement from the Swiss drugmaker. More »
A general view shows Swiss biotech group Actelion Headquarters in Allschwil near Basel February 17, 2015. REUTERS/Arnd Wiegmann Actelion (ATLN.S) has confirmed it has been approached by Johnson & Johnson (JNJ.N) about a possible transaction to take over the Sw... More »
A general view shows Swiss biotech group Actelion Headquarters in Allschwil near Basel February 17, 2015. REUTERS/Arnd Wiegmann U.S. healthcare company Johnson & Johnson (JNJ.N) said on Friday it was in preliminary talks with Actelion (ATLN.S) about a potentia... More »
